BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement f...(d uncertainties and a number of factorsb...),Health

Date:1/6/2009

d uncertainties, and a number of factors, both foreseen and unforeseen, that could cause actual results to differ materially from BioMarin and La Jolla's current expectations. Forward-looking statements include those that express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. There can be no assurance that actual results will be consistent the expectations reflected in BioMarin and La Jolla's forward looking statements. For example, there can be no assurance that: the ASPEN trial will be successful or that Riquent will be approved for marketing; the ASPEN trial will proceed on schedule as currently planned; La Jolla will receive any contingent payments under the license agreement with BioMarin or even if Riquent is approved, that it will be successfully marketed. These or other risks are discussed under the caption "Risk Factors" in BioMarin and La Jolla's most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as filed with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. We expressly disclaim any intent to update forward-looking statements.

    BioMarin Pharmaceutical Inc.             La Jolla Pharmaceutical Company

    Investors                                Investors
    Eugenia Shen                             Andrew Wiseman, Ph.D.
    (415) 506-6570                           (858) 646-6615
    eshen@bmrn.com                           andrew.wiseman@ljpc.com

    Media                                    Media
    Susan Berg                               Edward Agne
    (415) 506-6594                           The Communications Strategy Group
    sberg@bmrn.com                           (781) 631-3117
                                             '/>"/>
SOURCE  BioMarin Pharmaceutical Inc.; La Jolla Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 
Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference